ElsaLys Biotech acquires rights of Transgene’s anti-CD115 antibody
- Initially developed by Transgene, one of ElsaLys Biotech’s founding shareholders, this antibody inhibits a deleterious subpopulation of macrophages found in the tumor microenvironment.
- Based on the initial preclinical data, ElsaLys Biotech will give priority to developing ELB 041 (anti-CD115) in immuno-oncology, the goal being to launch a first clinical trial in 24 months.
- ElsaLys Biotech is now conducting five antibody programs in oncology and ophthalmology.
Read the press release
Diary - News
All news ElsaLys Biotech acquires rights of Transgene’s anti-CD115 antibody 